Literature DB >> 9178870

Characterization of neuropeptide Y receptor subtypes in the normal human brain, including the hypothalamus.

D Jacques1, Y Dumont, A Fournier, R Quirion.   

Abstract

The aim of the present study was to investigate the existence and distribution of neuropeptide Y receptor subtypes in various regions of the normal human brain using the peptide YY derivative receptor probes, [125I][Leu31,Pro34]polypeptide YY/Y1 and [125I]polypeptide YY(3-36)/Y2, in addition to the non-selective ligand [125I]polypeptide YY. Membrane binding assays performed with post mortem frontal cortex homogenates revealed that [125I]polypeptide YY and [125I]polypeptide YY(3-36) bound in a time- and protein concentration-dependent manner. Very low amounts of specific [125I][Leu31,Pro34]polypeptide YY binding could be detected even in the presence of high amounts of protein, contrasting with results obtained with [125I]polypeptide YY and [125I]polypeptide YY(3-36), a preferential Y2 receptor probe. Analysis of saturation isotherms revealed that [125I]polypeptide YY(3-36) bound to a single class of high-affinity sites (0.5-2 nM). Significantly higher binding capacities were evident for [125I]polypeptide YY(3-36) as compared to [125I][Leu31,Pro34]polypeptide YY, suggesting that the human frontal cortex, in contrast to the rat, is mostly enriched with Y2 receptors. Ligand selectivity profile confirmed the hypothesis that polypeptide YY(3-36), neuropeptide Y and polypeptide YY but not the [Leu31,Pro34] derivatives are potent competitors of [125I]polypeptide YY and [125I]polypeptide YY(3-36) binding sites. Autoradiographic studies demonstrated further that cortical areas, as well as most other regions of the human brain, are particularly enriched with Y2/[125I]polypeptide YY(3-36) sites, while only low to very low amounts of Y1 binding were detected except in the dentate gyrus of the hippocampal formation. In the human hypothalamus, a preponderance of Y2 binding sites was also noted. Taken together, these results clearly establish that the distribution of the Y1 and Y2 receptor subtypes in human is different from the rodent brain, the Y2 subtype being most abundant in the human brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178870     DOI: 10.1016/s0306-4522(96)00639-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  Football and doping: study of African amateur footballers.

Authors:  P F M Ama; B Betnga; V J Ama Moor; J P Kamga
Journal:  Br J Sports Med       Date:  2003-08       Impact factor: 13.800

4.  Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Authors:  K L Seldeen; P G Halley; C H Volmar; M A Rodríguez; M Hernandez; M Pang; S K Carlsson; L J Suva; C Wahlestedt; B R Troen; S P Brothers
Journal:  Neuropeptides       Date:  2017-11-07       Impact factor: 3.286

5.  Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy.

Authors:  S Furtinger; S Pirker; T Czech; C Baumgartner; G Ransmayr; G Sperk
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

6.  Localization of neuropeptide Y1 receptor immunoreactivity in the rat retina and the synaptic connectivity of Y1 immunoreactive cells.

Authors:  Iona D'Angelo; Su-Ja Oh; Myung-Hoon Chun; Nicholas C Brecha
Journal:  J Comp Neurol       Date:  2002-12-23       Impact factor: 3.215

7.  Distribution of neuropeptide Y-immunoreactive neurons in the human brainstem, cerebellum, and cortex during development.

Authors:  Sen Mun Wai; Pawel M Kindler; Edward T K Lam; Aiqun Zhang; David T Yew
Journal:  Cell Mol Neurobiol       Date:  2004-10       Impact factor: 5.046

8.  Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.

Authors:  Yvan Dumont; Mira Thakur; Annette Beck-Sickinger; Alain Fournier; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain.

Authors:  Y Dumont; A Fournier; R Quirion
Journal:  J Neurosci       Date:  1998-08-01       Impact factor: 6.167

10.  Altered expression of neuropeptide Y receptors caused by focal cortical dysplasia in human intractable epilepsy.

Authors:  Lin Li; Jiahui Deng; Changqing Liu; Hanjiang Luo; Yuguang Guan; Jian Zhou; Xueling Qi; Tianfu Li; Zhiqing David Xu; Guo-Ming Luan
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.